分析
2026年9月22日•1分で読めます
Celltrion's OmliClon Biosimilar Gains Strong Market Share in Europe
Celltrion's omalizumab biosimilar OmliClon expands to 26 European countries, achieving over 90% market share in Spain and exceeding sales targets in Italy.
分析
2026年9月7日•1分で読めます
Celltrion's Ramcima SC and US Zimpenra post 4.56 trillion KRW H1 sales
Ramcima SC and Zimpenra together generated 4.562 trillion KRW in the first half of the year, with strong growth in Europe and the US.
分析
2026年9月6日•1分で読めます
Celltrion expands Omliclo omalizumab biosimilar line with 300 mg launch in Europe
Celltrion has introduced the 300 mg dose of its omalizumab biosimilar Omliclo in Germany, the UK and France, extending its European portfolio for chronic urticaria and allergic asthma.
分析
2026年9月3日•1分で読めます
Celltrion Accelerates Biosimilar Growth in Europe and US, Launches CT-P68 Trial
Celltrion’s biosimilar business is building a virtuous growth cycle, expanding sales in Europe and the US while initiating a Phase 1 trial of CT-P68, a tremfya biosimilar.
分析
2026年8月31日•1分で読めます
Celltrion Biosimilars Gain Momentum in Europe, Omliclo Reaches 16% Share Q1
Celltrion's follow‑on biosimilars are expanding in Europe, with Omliclo achieving about 16% market share in Q1 2024, driven by a first‑mover strategy and direct sales network.
分析
2026年8月30日•1分で読めます
Celltrion’s bevacizumab biosimilar ‘베그젤마’ added to major US PBM formularies
Celltrion’s biosimilar 베그젤마 (bevacizumab) has been listed in Express Scripts and Optum formularies, strengthening its US oncology market foothold.
7
分析
2026年8月30日•1分で読めます
Celltrion Beats Q2 Market Expectations, Analysts Raise Target Prices
Celltrion reported Q2 revenue of 1.3 trillion KRW and operating profit of 430 billion KRW, surpassing consensus estimates, prompting analysts to lift target prices.